Navigation Links
VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ
Date:9/18/2009

SAN FRANCISCO, Sept. 18 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on September 15, 2009, it received a deficiency letter from the NASDAQ Stock Market stating that the Company is not in compliance with the minimum $1.00 per share bid price requirement for continued listing, as set forth in Listing Rule 5550(a)(2), and that the Company's securities are, therefore, subject to delisting from The NASDAQ Capital Market.

The Company has a period of 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price listing requirement. If at any time during this grace period the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Company will receive written notification of its compliance with the minimum bid price listing requirement. In the event the Company does not regain compliance prior to the expiration of the grace period, the Company will receive written notification that its securities are subject to delisting. In such event, the Company may appeal NASDAQ's determination to a NASDAQ Listing Qualifications Panel (the "Panel"), which request will stay the delisting of the Company's securities pending the Panel's decision. Additionally, the Company has had a hearing with the Panel regarding its failure to meet capitalization requirements for continued listing and is awaiting a decision from the Panel. There can be no assurance that the Company will regain compliance with the minimum bid price listing or capitalization requirements and maintain its NASDAQ listing.

About VIA Pharmaceuticals, Inc.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Valeant Pharmaceuticals to Present at the UBS Global Life Sciences Conference
2. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
3. AUDIO from Medialink and Solvay Pharmaceuticals: New High Five Program Addresses Energy Levels of Overweight Men
4. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
5. Merz Pharmaceuticals Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
6. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
7. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
8. Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
9. Reportlinker Adds US and European Radiopharmaceuticals Market Report
10. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
11. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Neil Haley, the Total Tutor host of the Simply ... about the importance of capacity to grow a business. , ... and is now a 5 Star Ambassador, Vi Millionaire, and ... titled "The Playful and Powerful Warrior Within You!" and holds ... out for over 1000 days straight. He is also ...
(Date:8/27/2014)... York, NY (PRWEB) August 27, 2014 Overcoming ... failure, he finally found his niche. The Women’s Radio Network, ... Armstrong for his continued support and dedication to the WRNW1 ... be able to have such a positive atmosphere.” After KC ... on Sirius XM of the Howard Stern show, “Howard 100 ...
(Date:8/27/2014)... 2014 A recently published study ... of time in correcting coagulopathy to prevent permanent injury ... of anticoagulants and examines medical conditions alleged to be ... although anticoagulants have been approved by the FDA to ... are also known to affect the consistency of the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The use ... quality of life and may eliminate the need for ... During a recent AllMed webinar, Dr. Zanhua Yi, board ... related to determining medical necessity of erythropoiesis-stimulating agents (ESAs) ... (CKD). , The U.S. Food and Drug Administration (FDA) ...
(Date:8/27/2014)... August 27, 2014 iHire was ... as the “Most Creative Workplace” in Frederick, a ... Places to Work Awards. , Held at the ... is a joint partnership between the Frederick County ... Development, Frederick County Business Development and Retention, and ...
Breaking Medicine News(10 mins):Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 3Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:iHire Named Most Creative Workplace in Frederick, MD 2
... March 3, 2008 The International AIDS Vaccine Initiative ... Fund, a new funding mechanism that will identify and ... AIDS vaccine research field. This initial project will apply ... the size of a small coin, which has the ...
... a new genetic risk factor for coeliac disease, have, ... implicated in causing the condition. The team, lead by ... and The London School of Medicine and Dentistry, have ... now know, four of these are also predisposing factors ...
... March 2 Therap Services announces the,release of version ... applications. Therap version 7.2 will feature,new forms such as ... module and the Emergency Medical/Behavior Intervention Strategies,(EMBIS) form in ... 7.2 include: -- Behavior Plan and Behavior Event ...
... Incontinence, dropped organs not just a function of age, study ... women in the United States have one or more pelvic ... disorders, says a Kaiser Permanente study. , Frequent urge to ... of such disorders. , The study of 4,000 women (80 ...
... Md. and ST. PAUL, Minn., Feb. 29 /PRNewswire-USNewswire/,-- ... Society &,Family Services, application for full Hague Accreditation ... This achievement of Hague,Accreditation demonstrates CHSFS, commitment to ... and abroad., The Hague Convention on Protection ...
... OAKLAND, Calif., Feb. 29 California,s,largest nonprofit hospital ... negotiations Thursday covering 15,000 hospital,workers across California., ... of negotiations underway and,continue their joint efforts to ... services across the state. In 2004, Catholic Healthcare,West ...
Cached Medicine News:Health News:IAVI and VaxDesign partner to develop a clinical trial in a test tube for AIDS vaccines 2Health News:Scientists uncover further steps leading to celiac disease 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 3Health News:Pelvic Floor Disorders Affect 1 in 3 Women 2Health News:Children's Home Society & Family Services Achieves Full Hague Accreditation 2Health News:Catholic Healthcare West and SEIU Begin Negotiations for 15,000 Hospital Workers 2
(Date:8/27/2014)...  Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a ... be participating in the Morgan Stanley 2014 Global Healthcare ... York, New York , on Tuesday, September 9, ... Zimmer, will be presenting at 9:10 a.m. Eastern Time.  ... will join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) has ... (FDA) to initiate a Phase 1/2a clinical trial of ... cord injury.  The approved trial follows the successful completion ... and is designed to assess safety and activity of ... spinal cord injuries, the first targeted indication for AST-OPC1 ...
(Date:8/26/2014)... Malaysia , Aug. 27, 2014 ... health insurance are fuelling the demand for medical ... the rise of medical tourism, the inflow of ... increasing. The market will continue its steady ascent ... to age-related and non-communicable diseases, compelling significant investments ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4
Inquire...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
Medicine Products: